Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

A

Alizyme

Status and phase

Completed
Phase 1

Conditions

Obesity

Treatments

Drug: ATL-962

Study type

Interventional

Funder types

Industry

Identifiers

NCT00148382
ATL-962/191/CL

Details and patient eligibility

About

The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese

Full description

Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a person's diet, leading to weight reduction.

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Obese, otherwise-healthy subjects
  • Body mass index 30-45kg/m2

Exclusion criteria

  • Women who are pregnant or breast feeding
  • Any drug treatment within 2 weeks of commencement of dosing in this study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems